Nucletron B.V has been awarded a United States Patent (No. 6,454,696) and European Patent (EP 1070519 A1) covering an automated device and method for treatment of prostate cancer using the seedSelectron. The seedSelectron is the world's first automated system for permanent seed implant procedures.

With this patent, Nucletron continues its history of innovative solutions for the treatment of cancer with radiation therapy and is the worldwide leader in Brachytherapy. The new patents are the result of Nucletron's focused investment into the development of a completely new solution for the treatment of prostate cancer: the Nucletron FIRST system. The system has already received FDA 510(k) clearance, CE mark, and is now in clinical use in the United States and Europe. The Nucletron FIRST system is comprised of the seedSelectron in combination with SPOT PRO.

The seedSelectron significantly minimizes the preparation time for the seed implant operation and is designed to offer maximum radiation protection for the staff in the operating theatre. Integrated verification and quality assurance tools offer an unprecedented degree of safety and confidence during the implant operation.

In combination with SPOT PRO, Nucletron can provide a unique system for real-time 3-D treatment planning and delivery.

As a result, the treating clinician can instantly adapt a treatment plan based on the clinical findings during the implantation, leading to an optimal coverage of the prostate with the therapeutic dose.

The FIRST System offers a break-through treatment approach that increases the confidence of clinicians.